<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36854540</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Clinical associations of cognitive dysfunction in systemic lupus erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000835</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000835</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Cognitive dysfunction in SLE is common, but clinical risk factors are poorly understood. This study aims to explore the associations of cognitive dysfunction in SLE with disease activity, organ damage, biomarkers and medications.</AbstractText><AbstractText Label="METHODS">We performed cross-sectional cognitive assessment using a conventional neuropsychological test battery, with normative values derived from demographically matched healthy subjects. Endpoints included two binary definitions of cognitive dysfunction and seven individual cognitive domain scores. Clinical parameters included disease activity (SLEDAI-2K) and organ damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index). We performed regression analyses to determine associations between clinical parameters and cognitive endpoints.</AbstractText><AbstractText Label="RESULTS">89 patients with SLE were studied, with median age of 45 and disease duration of 15 years. Organ damage was significantly associated with severe cognitive dysfunction (OR 1.49, CI 1.01-2.22) and worse cognitive test performance in three of the seven individual cognitive domains. In contrast, no significant associations were found between SLEDAI-2K at the time of cognitive assessment and any cognitive endpoints on multivariate analysis. Higher time-adjusted mean SLEDAI-2K was associated with better verbal memory scores but had no significant associations with other cognitive endpoints. The presence of anti-dsDNA antibodies and high IFN gene signature were negatively associated with severe cognitive dysfunction; there were no significant associations with the other autoantibodies studied or any medications. Substance use was significantly associated with lower psychomotor speed. Only 8% of patients who had cognitive dysfunction on testing had been recognised by clinicians on their SDI score.</AbstractText><AbstractText Label="CONCLUSIONS">In SLE, cognitive dysfunction was positively associated with organ damage, but not associated with disease activity, and serological activity and high IFN signature were negatively associated. Cognitive dysfunction was poorly captured by clinicians. These findings have implications for preventative strategies addressing cognitive dysfunction in SLE.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raghunath</LastName><ForeName>Sudha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3062-7328</Identifier><AffiliationInfo><Affiliation>Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia sudha.raghunath@monash.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Department, Monash Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glikmann-Johnston</LastName><ForeName>Yifat</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golder</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Department, Monash Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandane-Rathnayake</LastName><ForeName>Rangi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morand</LastName><ForeName>Eric F</ForeName><Initials>EF</Initials><Identifier Source="ORCID">0000-0002-9507-3338</Identifier><AffiliationInfo><Affiliation>Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Department, Monash Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stout</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoi</LastName><ForeName>Alberta</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9416-7383</Identifier><AffiliationInfo><Affiliation>Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Department, Monash Health, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Competing interests: SR reports a research grant from Lupus Victoria and postgraduate scholarships from the National Health and Medical Research Council (NHMRC), Arthritis Australia and the Australian Rheumatology Association. YG-J, VG, RK-R and JCS have nothing to disclose. EFM reports grants from Abbvie, Amgen, AstraZeneca, Biogen, BristolMyersSquibb, Eli Lilly, EMD Serano, Genentech, GlaxoSmithKline, Janssen and UCB, as well as consulting fees from AstraZeneca, Biogen, BristolMyersSquibb, Eli Lily, EMD Serano, Novartis, Servier and Zenas, all of which were outside the submitted work. EFM also reports payment or honoraria for educational events from AstraZeneca, Gilead and ONO, meeting support from AstraZeneca, patents with Monash University and AstraZeneca and director role for Rare Voices Australia. AH reports grants from AstraZeneca and Merck Serono outside the submitted work, Sponsorship of the Australian Lupus Registry and Biobank which is chaired by AH is received from Janssen, BMS, AstraZeneca and UCB. AH also reports meeting support from Janssen and consulting fees from Abbvie, Janssen and GSK. AH is honorary treasurer and board member for the Australian Rheumatology Association.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>28</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36854540</ArticleId><ArticleId IdType="pmc">PMC9980376</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000835</ArticleId><ArticleId IdType="pii">10/1/e000835</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brey RL, Holliday SL, Saklad AR, et al. . Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002;58:1214&#x2013;20. 10.1212/wnl.58.8.1214</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.58.8.1214</ArticleId><ArticleId IdType="pubmed">11971089</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunath S, Guymer EK, Glikmann-Johnston Y, et al. . Patterns and prevalence of cognitive dysfunction in systemic lupus erythematosus. J Int Neuropsychol Soc 2022. 10.2139/ssrn.4162728</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4162728</ArticleId></ArticleIdList></Reference><Reference><Citation>Appenzeller S, Cendes F, Costallat LTL. Cognitive impairment and employment status in systemic lupus erythematosus: a prospective longitudinal study. Arthritis Rheum 2009;61:680&#x2013;7. 10.1002/art.24346</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24346</ArticleId><ArticleId IdType="pubmed">19405004</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunath S, Guymer EK, Glikmann-Johnston Y, et al. . Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus. Rheumatology (Oxford) 2022;62:190&#x2013;9. 10.1093/rheumatology/keac207</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac207</ArticleId><ArticleId IdType="pmc">PMC9788827</ArticleId><ArticleId IdType="pubmed">35383358</ArticleId></ArticleIdList></Reference><Reference><Citation>Arntsen K, Wildman P, Gross D. Lupus: patient voices. Joint report by Lupus Research Alliance, Lupus Foundation of America and Lupus and Allied Diseases Association for the CDER and FDA. 2018. Available: http://www.lupuspfdd.org/LupusPFDDReportwCover.pdf</Citation></Reference><Reference><Citation>Raghunath S, Glikmann-Johnston Y, Hanly JG, et al. . Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding? The Lancet Rheumatology 2022;4:e293&#x2013;302. 10.1016/S2665-9913(21)00331-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00331-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Loukkola J, Laine M, Ainiala H, et al. . Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. J Clin Exp Neuropsychol 2003;25:145&#x2013;51. 10.1076/jcen.25.1.145.13621</Citation><ArticleIdList><ArticleId IdType="doi">10.1076/jcen.25.1.145.13621</ArticleId><ArticleId IdType="pubmed">12607179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozora E, Ellison MC, West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004;51:810&#x2013;8. 10.1002/art.20692</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20692</ArticleId><ArticleId IdType="pubmed">15478145</ArticleId></ArticleIdList></Reference><Reference><Citation>Skeel RL, Johnstone B, Yangco DT, et al. . Neuropsychological deficit profiles in systemic lupus erythematosus. Appl Neuropsychol 2000;7:96&#x2013;101. 10.1207/S15324826AN0702_5</Citation><ArticleIdList><ArticleId IdType="doi">10.1207/S15324826AN0702_5</ArticleId><ArticleId IdType="pubmed">10863604</ArticleId></ArticleIdList></Reference><Reference><Citation>Monastero R, Bettini P, Del Zotto E, et al. . Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J Neurol Sci 2001;184:33&#x2013;9. 10.1016/s0022-510x(00)00492-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(00)00492-5</ArticleId><ArticleId IdType="pubmed">11231030</ArticleId></ArticleIdList></Reference><Reference><Citation>Shucard JL, Parrish J, Shucard DW, et al. . Working memory and processing speed deficits in systemic lupus erythematosus as measured by the paced auditory serial addition test. J Int Neuropsychol Soc 2004;10:35&#x2013;45. 10.1017/S1355617704101057</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1355617704101057</ArticleId><ArticleId IdType="pubmed">14751005</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura K, Omori M, Katsumata Y, et al. . Neurocognitive impairment in corticosteroid-naive patients with active systemic lupus erythematosus: a prospective study. J Rheumatol 2015;42:441&#x2013;8. 10.3899/jrheum.140659</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.140659</ArticleId><ArticleId IdType="pubmed">25593228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kello N, Anderson E, Diamond B. Cognitive dysfunction in systemic lupus erythematosus: a case for initiating trials. Arthritis Rheumatol 2019;71:1413&#x2013;25. 10.1002/art.40933</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40933</ArticleId><ArticleId IdType="pmc">PMC6716992</ArticleId><ArticleId IdType="pubmed">31102496</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamintsky L, Beyea SD, Fisk JD, et al. . Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment. Ann Rheum Dis 2020;79:1580&#x2013;7. 10.1136/annrheumdis-2020-218004</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218004</ArticleId><ArticleId IdType="pubmed">33004325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarfeshani A, Carroll KR, Volpe BT, et al. . Cognitive impairment in SLE: mechanisms and therapeutic approaches. Curr Rheumatol Rep 2021;23:1&#x2013;19. 10.1007/s11926-021-00992-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-00992-1</ArticleId><ArticleId IdType="pubmed">33782842</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill S, Morand EF, Hoi A. The Australian Lupus Registry and Biobank: a timely initiative. Med J Aust 2017;206:194&#x2013;5. 10.5694/mja16.01282</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja16.01282</ArticleId><ArticleId IdType="pubmed">28301780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573&#x2013;7. 10.7326/0003-4819-147-8-200710160-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-147-8-200710160-00010</ArticleId><ArticleId IdType="pubmed">17938396</ArticleId></ArticleIdList></Reference><Reference><Citation>The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599&#x2013;608. 10.1002/1529-0131(199904)42:4&lt;599::AID-ANR2&gt;3.0.CO;2-F</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199904)42:4&lt;599::AID-ANR2&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10211873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozora E, Thompson LL, West SG, et al. . Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996;39:2035&#x2013;45. 10.1002/art.1780391213</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780391213</ArticleId><ArticleId IdType="pubmed">8961909</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietaharju A, Auvinen A. Validity and reliability of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus: comment on the article by Kozora et al. Arthritis Rheum 2005;53:478&#x2013;9; 10.1002/art.21183</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21183</ArticleId><ArticleId IdType="pubmed">15934124</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghunath S, Glikmann-Johnston Y, Morand E, et al. . Evaluation of the Montreal cognitive assessment as a screening tool for cognitive dysfunction in SLE. Lupus Sci Med 2021;8:e000580. 10.1136/lupus-2021-000580</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000580</ArticleId><ArticleId IdType="pmc">PMC8679063</ArticleId><ArticleId IdType="pubmed">34911821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ad Hoc Committee on Lupus Response Criteria: Cognition Sub-committee, Mikdashi JA, Esdaile JM, et al. . Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 2007;16:418&#x2013;25. 10.1177/0961203307079044</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307079044</ArticleId><ArticleId IdType="pubmed">17664232</ArticleId></ArticleIdList></Reference><Reference><Citation>Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 2010;19:49&#x2013;51. 10.1177/0961203309346505</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309346505</ArticleId><ArticleId IdType="pubmed">19910390</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanou A, Chakravarty E, James JA, et al. . Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Sci Med 2014;1:e000005. 10.1136/lupus-2013-000005</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2013-000005</ArticleId><ArticleId IdType="pmc">PMC4225744</ArticleId><ArticleId IdType="pubmed">25396057</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, et al. . The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363&#x2013;9. 10.1002/art.1780390303</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T, et al. . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295&#x2013;306. 10.1111/j.1538-7836.2006.01753.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolopoulos D, Vincent F, Hoi A, et al. . Associations of metabolic syndrome in SLE. Lupus Sci Med 2020;7:e000436. 10.1136/lupus-2020-000436</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000436</ArticleId><ArticleId IdType="pmc">PMC7668361</ArticleId><ArticleId IdType="pubmed">33188034</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti KGMM, Eckel RH, Grundy SM, et al. . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640&#x2013;5. 10.1161/CIRCULATIONAHA.109.192644</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.192644</ArticleId><ArticleId IdType="pubmed">19805654</ArticleId></ArticleIdList></Reference><Reference><Citation>Northcott M, Jones S, Koelmeyer R, et al. . Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. Lupus Sci Med 2022;9:e000625. 10.1136/lupus-2021-000625</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000625</ArticleId><ArticleId IdType="pmc">PMC8867321</ArticleId><ArticleId IdType="pubmed">35197305</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezak MD, Howieson DB, Bigler ED, et al. . Neuropsychological assessment. 5th ed. New York, NY, US: Oxford University Press, 2012.</Citation></Reference><Reference><Citation>Conti F, Alessandri C, Perricone C, et al. . Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One 2012;7:e33824. 10.1371/journal.pone.0033824</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033824</ArticleId><ArticleId IdType="pmc">PMC3312889</ArticleId><ArticleId IdType="pubmed">22461897</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorman G, Micelli M, Cosentino V, et al. . Disfunci&#xf3;n cognitiva en lupus eritematoso sist&#xe9;mico y su asociaci&#xf3;n con actividad y da&#xf1;o. Medicina (B Aires) 2017;77:257&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">28825566</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 2004;43:1555&#x2013;60. 10.1093/rheumatology/keh384</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh384</ArticleId><ArticleId IdType="pubmed">15342927</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin EY, Holliday SL, Williams P, et al. . Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2005;64:297&#x2013;303. 10.1212/01.WNL.0000149640.78684.EA</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000149640.78684.EA</ArticleId><ArticleId IdType="pubmed">15668428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli F, Perricone C, Pirone C, et al. . Cognitive dysfunction improves in systemic lupus erythematosus: results of a 10 years prospective study. PLoS One 2018;13:e0196103. 10.1371/journal.pone.0196103</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0196103</ArticleId><ArticleId IdType="pmc">PMC5933733</ArticleId><ArticleId IdType="pubmed">29723209</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte-Garc&#xed;a A, Romero-D&#xed;az J, Ju&#xe1;rez S, et al. . Disease activity, autoantibodies, and inflammatory molecules in serum and cerebrospinal fluid of patients with systemic lupus erythematosus and cognitive dysfunction. PLoS One 2018;13:e0196487. 10.1371/journal.pone.0196487</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0196487</ArticleId><ArticleId IdType="pmc">PMC5933704</ArticleId><ArticleId IdType="pubmed">29723220</ArticleId></ArticleIdList></Reference><Reference><Citation>Paez-Venegas N, Jordan-Estrada B, Chavarria-Avila E, et al. . The Montreal cognitive assessment test: a useful tool in screening of cognitive impairment in patients with systemic lupus erythematosus. J Clin Rheumatol 2019;25:325&#x2013;8. 10.1097/RHU.0000000000000876</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0000000000000876</ArticleId><ArticleId IdType="pmc">PMC7597762</ArticleId><ArticleId IdType="pubmed">31764492</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbotte RM, Denburg SD, Denburg JA. Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J Rheumatol 1995;22:863&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8587073</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai L, Asaduzzaman A, Noamani B, et al. . The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res Ther 2021;23:29. 10.1186/s13075-021-02414-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02414-0</ArticleId><ArticleId IdType="pmc">PMC7811214</ArticleId><ArticleId IdType="pubmed">33451338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialas AR, Presumey J, Das A, et al. . Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature 2017;546:539&#x2013;43. 10.1038/nature22821</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22821</ArticleId><ArticleId IdType="pubmed">28614301</ArticleId></ArticleIdList></Reference><Reference><Citation>Rushton JP, Jensen AR. Thirty years of research on race differences in cognitive ability. Psychology, Public Policy, and Law 2005;11:235&#x2013;94. 10.1037/1076-8971.11.2.235</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/1076-8971.11.2.235</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Connelly K, Staples M, et al. . Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus 2013;22:1425&#x2013;30. 10.1177/0961203313500547</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313500547</ArticleId><ArticleId IdType="pubmed">23942610</ArticleId></ArticleIdList></Reference><Reference><Citation>Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:1311&#x2013;20. 10.1002/art.1780370907</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780370907</ArticleId><ArticleId IdType="pubmed">7945494</ArticleId></ArticleIdList></Reference><Reference><Citation>Latvala A, Castaneda AE, Per&#xe4;l&#xe4; J, et al. . Cognitive functioning in substance abuse and dependence: a population-based study of young adults. Addiction 2009;104:1558&#x2013;68. 10.1111/j.1360-0443.2009.02656.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1360-0443.2009.02656.x</ArticleId><ArticleId IdType="pubmed">19686526</ArticleId></ArticleIdList></Reference><Reference><Citation>Heflin LH, Meyerowitz BE, Hall P, et al. . Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst 2005;97:854&#x2013;6. 10.1093/jnci/dji137</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/dji137</ArticleId><ArticleId IdType="pubmed">15928306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan A, Marzouk S, Ghanean H, et al. . Assessment of the psychometric properties of patient-reported outcomes of depression and anxiety in systemic lupus erythematosus. Semin Arthritis Rheum 2019;49:260&#x2013;6. 10.1016/j.semarthrit.2019.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.03.004</ArticleId><ArticleId IdType="pubmed">30940467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Petri M, Alarc&#xf3;n GS, et al. . Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. J Rheumatol 2009;36:82&#x2013;8. 10.3899/jrheum.080212</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.080212</ArticleId><ArticleId IdType="pmc">PMC2944223</ArticleId><ArticleId IdType="pubmed">19004039</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>